What is OPDIVO SC used for?

( ARTG ) Melanoma,OPDIVO, as monotherapy, is indicated for the adjuvant treatment of adults and adolescent patients 12 years and older with completely resected Stage IIB, IIC, III or IV melanoma. OPDIVO, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma. OPDIVO, in combination with ipilimumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. The approval of this indication is based on a pre-specified comparis

What are the side effects of OPDIVO SC?

You can help ensure medicines are safe by reporting the side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Does OPDIVO SC interact with other medications?

No formal drug interactions have been carried out for nivolumab.

Can OPDIVO SC be used during pregnancy?

( AHT ) For the active ingredient nivolumab You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What precautions should be taken with OPDIVO SC?

• Nivolumab treatment might result in side effects like immune-mediated pneumonitis (lung inflammation), colitis (inflammation of the intestines), hepatitis, kidney dysfunction and thyroid disorders. Consult your physician immediately if any signs or symptoms of these conditions are seen after taking nivolumab. • • Symptoms like chest pain, severe cough, breathing difficulties, abdominal pain, diarrhea, jaundice, ankle swelling, hormonal problems, muscle weakness or changes in vision shou

What ATC class does OPDIVO SC belong to?

OPDIVO SC: ATC L01FF01. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

OPDIVO SC

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

USDailyMed:Nivolumab AU:DUse is not recommended L01FF01(WHO) AU:S4(Prescription only)CA:℞-only/Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-onlyIn general: ℞ (Prescription only) 946414-94-4 DB09035 none 31YO63LBSN D10316 ChEMBL2108738 Nivolumab, sold under thebrand nameOpdivo, is ananti-cancer medicationin the class ofimmune checkpoint inhibitors. It selectively binds and blocks theprogrammed death-1(PD-1) receptor onT cells, thereby facilitating their activation. It is used to treat certain types ofcancerincludingmelanoma,lung cancer,malignant pleural mesothelioma,renal cell carcinoma,Hodgkin lymphoma,head and neck cancer,urothelial carcinoma,colon cancer,esophageal squamous cell carcinoma,liver cancer,gastric cancer, and esophageal or gastroesophageal junction cancer.It is administeredintravenously. The most common side effects include fatigue, rash, musculoskeletal pain,pruritus(itching),diarrhea,nausea,asthenia(weakness), cough,dyspnea(shortness of breath), constipation, decreased appetite, back pain,arthralgia(joint pain), upper respiratory tract infection,pyrexia(fever),headache, abdominal pain, and vomiting.Use during pregnancy may harm the baby.Nivolumab is a humanIgG4monoclonal antibodythatblocks PD-1.It is a type ofimmunotherapyand works as acheckpoint inhibitor, blocking a signal that prevents activation ofT cellsfrom attacking the cancer.The most common side effects when used in combination with chemotherapy include peripheral neuropathy (damage to the nerves outside of the brain and spinal cord), nausea, fatigue, diarrhea, vomiting, decreased appetite, abdominal pain, constipation and musculoskeletal pain. Nivolumab was approved for medical use in the United States in 2014.Nivolumab is a therapeutic alternative on theWorld Health Organization's List of Essential Medicines.It is made usingChinese hamster ovary cells.Nivolumab is the second FDA-approved systemic therapy for mesotheliomaand is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

OPDIVO SC

User Reviews